Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China Food And Drug Administration
Biotech
Hutchmed eyes China approval for autoimmune drug after ph. 3 win
Hutchmed is gearing up to submit sovleplenib for approval in the company’s native China after the Syk inhibitor scored a phase 3 win.
James Waldron
Aug 21, 2023 8:45am
Beijing’s CANbridge brings on Pfizer rare disease leader as CMO
Jul 31, 2018 9:31am
LivaNova to offload Cardiac Rhythm unit for $190M
Nov 20, 2017 10:42am
Sinovac to go private amid bribery concerns
Jun 30, 2017 6:48am
